Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
56.45 USD | -0.05% | +1.07% | +25.64% |
08.03. | Novo Nordisk hofft, experimentelles Medikament gegen Fettleibigkeit noch in diesem Jahrzehnt auf den Markt zu bringen | RE |
07.03. | Transcript : Catalent, Inc. - Special Call |
ETFs investiert in Catalent, Inc.
Name | Gewichtung | Volumen | % 1. Jan. | Investm. Rating |
---|---|---|---|---|
1,35% | 2 M€ | -.--% | ||
1,21% | 8 M€ | +6.91% | ||
0,83% | 2 M€ | +12.97% | ||
0,60% | 18 M€ | +6.77% | - | |
0,48% | 7 M€ | -.--% | - | |
0,40% | 92 M€ | +0.06% | - | |
0,22% | 9 M€ | -.--% | - | |
0,21% | 7 M€ | +7.68% | - | |
0,21% | 32 M€ | +3.80% | - | |
0,21% | 17 M€ | +7.68% | - | |
0,09% | 2 399 M€ | +14.49% | ||
0,08% | 5 M€ | -72.95% | - | |
0,07% | 19 M€ | +6.85% | - | |
0,07% | 676 M€ | +10.22% | ||
0,06% | 268 M€ | -.--% | - | |
0,06% | 193 M€ | +10.35% | - | |
0,06% | 460 M€ | +12.36% | ||
0,05% | 26 M€ | +16.66% | - | |
0,05% | 2 711 M€ | +12.71% | - | |
0,04% | 36 M€ | -.--% | ||
0,04% | 274 M€ | +15.20% | ||
0,04% | 55 M€ | +17.14% | - | |
0,03% | 276 M€ | +11.40% | - | |
0,03% | 0 M€ | 0.00% | - |
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+25.64% | 10.2 Mrd. | |
+33.46% | 701 Mrd. | |
+26.24% | 570 Mrd. | |
+0.93% | 381 Mrd. | |
+21.03% | 334 Mrd. | |
+17.51% | 322 Mrd. | |
+0.74% | 209 Mrd. | |
+2.95% | 212 Mrd. | |
-6.05% | 205 Mrd. | |
-3.61% | 157 Mrd. |
- Börse
- Aktien
- Aktie Catalent, Inc. - Nyse
- ETFs Catalent, Inc.